Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007035 | 0.89 | MEN1 (0.76) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL5183678 | 0.86 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL30738420 | 0.86 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL14899353 | 0.86 | ALDH1A1 (0.67) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL5188518 | 0.84 | GAA (0.81) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL31561745 | 0.84 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL3129403 | 0.84 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL31590799 | 0.84 | KMT2A (0.69) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL9191016 | 0.84 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL1645833 | 0.84 | ADRA2C (0.67) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-07-12 | — | — | US | disclosed |
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | HERIOT-WATT UNIVERSITY (GB) | 2017-12-21 | — | — | US | disclosed |
| EP-2474545-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2426129-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2455382-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016092327-A1 | PRO-SURVIVAL COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2008042362-A1 | ARYLAMINO-ARYLPROPANOLAMINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | JANSSENS FRANS EDUARD | 2008-03-20 | — | — | US | disclosed |
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | JANSSENS FRANS EDUARD | 2008-03-20 | — | — | US | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| EP-0292911-A2 | Process for the preparation of pure nitro-aminobenzene-compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | SMN1; SMN2 3460/4885ALDH1A1 1439/4885MEN1 3633/4885 |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | HTR2C, HTR2A, HTR1A | SMN1; SMN2 979/4885ALDH1A1 349/4885MEN1 3656/4885 |
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | MCL1, MKI67, MORF4L1 | SMN1; SMN2 10/4885ALDH1A1 95/4885MEN1 2331/4885 |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | SMN1; SMN2 3296/4885ALDH1A1 1111/4885MEN1 3889/4885 |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | SMN1; SMN2 3454/4885ALDH1A1 1194/4885MEN1 3885/4885 |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | IDE, SI, GPR119 | SMN1; SMN2 3454/4885ALDH1A1 1194/4885MEN1 3885/4885 |
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | OPRL1, OPRK1, OPRM1 | SMN1; SMN2 1834/4885ALDH1A1 783/4885MEN1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.